Skip Navigation

Carl Novina, MD, PhD



  • Principal Investigator, Cancer Immunology and Virology, Dana-Farber Cancer Institute
  • Associate Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical School
  • Associate Member, Broad Institute of Harvard and MIT

Contact Information

  • Office Phone Number(617) 582-7961
  • Fax(617) 582-7962


Dr. Novina received his M.D. from Columbia University, College of Physicians and Surgeons in 2000 and his Ph.D. from Tufts University, Sackler School of Graduate Biomedical Sciences in 1998. His graduate work resulted in 10 publications examining transcriptional regulation of TATA-less promoters in Ananda Roy’s laboratory. As a postdoctoral fellow in Phillip Sharp’s laboratory at the Massachusetts Institute of Technology, Dr. Novina studied the basic mechanisms of microRNAs, demonstrated the use of siRNAs to inhibit HIV infection (Nat Med. 8:681, 2002) and developed one of the first lentiviruses for the delivery of siRNAs to non-dividing mammalian cells (RNA 9:493, 2003), which became the host vector for The RNAi Consortium’s collection of lentivirus-expressed siRNAs.

In 2004, Dr. Novina joined the faculty at Dana-Farber Cancer Institute and Harvard Medical School. His laboratory has made several seminal insights into the fundamental biology of microRNAs and their dysregulation in cancers. His group reported the first fully cell-free microRNA-dependent translational repression reactions (Mol. Cell 22:553, 2006), used these reactions to reveal how microRNAs repress translation initiation by blocking 60S subunit joining to 40S ribosomes (PNAS 105:5343, 2008), discovered an RNA chaperone activity intrinsic to human Argonaute proteins (NSMB 16:1259, 2009) and an alternate mechanism of RISC assembly by Argonaute recruitment to microRNA-mRNA duplexes in vitro and in cells (RNA 18:2041, 2012), demonstrated the first example of an intronic microRNA (miR-211) that assumes the tumor suppressor role of its host gene (melastatin; Mol. Cell 40:841, 2010) and direct coupling between melastatin splicing and miR-211 microprocessing (PLoS Genet. (7)10:e10023302011, 2011). His group recently uncovered a potential tumor suppressor role for ribosomes in regulating microRNA function (Mol. Cell 46:171, 2012).


Epigenetic engineering cancer immunotherapy

The Novina lab has focused on the molecular mechanisms of microRNAs and their dysregulation in cancers. Indeed, it is critical to understand how microRNA expression is controlled in normal and disease contexts. In mammals, many microRNAs are developmentally regulated and demonstrate altered epigenetic profiles, such as aberrant promoter hypo- and hyper-methylation, in cancers. Altered microRNA expression has been correlated with the tissue of origin, prognosis, and drug sensitivity of cancers and other diseases. To study the causes and consequences of inappropriate DNA methylation of microRNA and other disease-causing genes, the Novina lab is developing "epigenetic engineering" tools that will facilitate site-specific addition and removal of methyl groups on DNA.

To accomplish this, we have been employing the RNA-directed CRISPR-Cas9 system. There are two key components to this system that can be leveraged for epigenetic reprogramming: (1) the Cas9 protein is directed to specific DNA sequences by a complementary guide RNA (gRNA). Introducing multiple gRNAs can direct Cas9 to multiple sites within a promoter or to multiple different promoters simultaneously. (2) Cas9 is normally an endonuclease that cleaves foreign DNA; however, an endonuclease-deficient Cas9 (dCas9) mutant allows localization of dCas9 without cleavage. To methylate or demethylate DNA at precise sites in the genome, we have fused methyltransferases (MTases) or demethylases to dCas9. To avoid deleterious effects of off-target methylation/demethylation, we took a "split-fusion" approach in which the enzyme is split into two inactive halves that only regain functionality when co-recruited to a particular site. These dCas9-fusion proteins bound to selected gRNAs will allow us to specifically target discrete loci for repression (methylation) or induction (demethylation) of genes of interest.

Precise control over DNA methylation will enable specific reprogramming of cell fates for experimental and therapeutic purposes. My lab is using these tools to (1) relate differential promoter methylation to changes in chromatin architecture and transcription factor binding at promoters; (2) compare methylation-dependent changes in microRNA transcription to oncogenic phenotypes; and (3) develop epigenetic reprogramming strategies for a variety of human diseases. A major initiative in my lab is using dCas9-MTases to target genes that repress immune responses. Our goal is to silence repressive protein-coding and non-coding genes to improve the efficacy of T cell-based cancer immunotherapy. We believe that a robust platform for epigenetic engineering will enable novel therapies against cancer and other diseases.


Dana-Farber Cancer Institute
450 Brookline Avenue, Smith 570
Boston, MA 02215
Get Directions